Patients with ALK fusion NSCLC are frequently treated with serial generations of ALK inhibitors, but resistance almost always develops—through acquired single point mutations in the ALK TKD in approximately one-third of cases13. The gene discussed is ALK; the disease is non-small cell lung carcinoma.